Author: Vitaliy Dadalyan

Wall Street Is Throwing Billions at Once-Shunned Gold Miners

(Bloomberg) -- A year ago, you couldn’t get Wall Street to touch most gold miners’ stocks. Today, it’s throwing billions at the industry.Precious-metals miners once seen as too leveraged and high-risk for the typical investor raised $2.4 billion in secondary equity offerings during the second quarter, data compiled by Bloomberg show. That’s the most since 2013 and seven times more than the funds they raised a year earlier.With the Covid-19 crisis threatening economies worldwide and gold prices soaring on the heels of monetary and stimulus programs, precious-metals companies have become the darlings of the investment community. The sector, which once largely drew the attention of specialist funds, is now attracting a broad base of investors.“All of a sudden we’re seeing real interest from generalists,” said Bryan Slusarchuk, chief executive officer of Fosterville South Exploration Ltd., whose company plans to dig for gold in Australia. “If this continues, it could just be...

Is Novavax’s (NVAX) Super-High Valuation Justified? This Analyst Says ‘Yes’

Can any superlatives be added to the increasingly long list of ones already used to describe Novavax’ (NVAX) progress in 2020? Words such as stupendous, incredible, and amazing can by now hardly do justice by to the meteoric- there’s another one - rise of the vaccine specialist. The evidence: Novavax’ share price has increased by 3,370% year-to-date.Apart from the early promise shown by its COVID-19 vaccine candidate, NVX-CoV2373, Novavax’ surge has been built on accelerating momentum. Eventually though, the vaccine player will have to back up the share gains, government grants and analysts’ ratings with positive trial results.NVAX’ latest surge (Friday’s 17% uptick) came following another price target raise from a long time NVAX bull. B Riley FBR analyst Mayank Mamtani raised his Novavax price target from $106 to $155, while reiterating a Buy rating on the stock. (To watch Mamtani’s track record, click here)Mamtani believes the biotech is most likely...